prednisone has been researched along with Mucositis in 15 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Mucositis: An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combination of everolimus and low-dose prednisone administered daily was hypothesized to prevent noninfectious pneumonitis (NIP) and mucositis, two common adverse events related to everolimus." | 5.24 | A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer. ( Amadori, D; Barone, D; Burgio, SL; De Giorgi, U; Gallà, V; Lolli, C; Maugeri, A; Schepisi, G; Vertogen, B, 2017) |
| "We reviewed published studies reporting phase II and III clinical trials of dose-dense regimens for breast cancer and NHL, TAC (docetaxel, adriamycin, cyclophosphamide) chemotherapy for breast cancer, and infusional 5-fluorouracil-based regimens for colorectal cancer." | 4.83 | Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. ( Avritscher, EB; Bekele, BN; Cooksley, CD; Elting, LS; Jones, JA; Michelet, M, 2006) |
| "The prognostic significance of O6-methylguanine DNA methyltransferase (MGMT) inactivation was evaluated in patients with diffuse large B-cell lymphoma (DLBCL) who received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in addition to rituximab." | 3.75 | Is inactivation of O6-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy? ( Kang, JH; Kim, DC; Kim, HG; Kim, IS; Ko, GH; Lee, GW; Lee, JH; Lee, JS; Song, DH; Yang, JW, 2009) |
| "Older patients with Burkitt lymphoma/leukemia (BL) have inferior outcomes." | 2.78 | Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia. ( Ambinder, RF; Bolaños-Meade, J; Borowitz, MJ; Brodsky, RA; Carraway, HE; Cho, SY; Crilley, PA; Gladstone, DE; Huff, CA; Jones, RJ; Kasamon, YL; Matsui, WH; Smith, BD; Swinnen, LJ; Tsai, HL, 2013) |
| "Of these patients, 22 (40%) had Burkitt's lymphoma (BKL), 22 (40%) had diffuse large B-cell lymphoma (DLBL) and 11 (20%) had anaplastic large T-cell lymphoma (ALCL)." | 2.72 | Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol. ( Guan, ZZ; He, YJ; Lin, JY; Lui, DG; Sun, XF; Wang, ZH; Xia, Y; Zhen, ZJ, 2006) |
| "The regimen for acute lymphocytic leukemia was idarubicin 8 mg/m2, dl - 3; vincristine 2 mg/mr, dl; cyclophosphamide 750 mg/m2, dl ; plus prednisone 60 mg/m(2),dl - 14 for 1-2 cycles." | 2.72 | [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia]. ( Du, X; Ke, XY; Liu, Y; Lu, ZS; Lv, JQ; Ma, J; Shen, ZX; Xu, XH; Zeng, XY; Zhan, ZM; Zhang, XH; Zhao, YM, 2006) |
| "Prednisone was increased 2 mg/kg/day for 2 weeks followed by slower tapering over a period of 5 months." | 1.48 | Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab. ( Acero Brand, FZ; Adam, JP; Blais, N; Faulques, B; Maietta, A; Soulières, D; Suter, N, 2018) |
| "Stevens-Johnson syndrome and toxic epidermal necrolysis are life-threatening dermatological conditions." | 1.42 | [Systemic lupus erythematosus presenting as Stevens-Johnson syndrome]. ( Bellakhal, S; Ben Kaab, B; Derbel, F; Douggui, MH; Souissi, A; Teyeb, Z, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, W | 1 |
| Zhang, Y | 1 |
| Zhang, L | 1 |
| Yang, C | 1 |
| Feng, J | 1 |
| Cai, H | 1 |
| Chen, M | 1 |
| Cao, X | 1 |
| Zhuang, J | 1 |
| Zhu, T | 1 |
| Duan, M | 1 |
| Zhang, W | 1 |
| Li, J | 1 |
| Zhou, D | 1 |
| Lolli, C | 1 |
| Gallà, V | 1 |
| Schepisi, G | 1 |
| Barone, D | 1 |
| Burgio, SL | 1 |
| Maugeri, A | 1 |
| Vertogen, B | 1 |
| Amadori, D | 1 |
| De Giorgi, U | 1 |
| Acero Brand, FZ | 1 |
| Suter, N | 1 |
| Adam, JP | 1 |
| Faulques, B | 1 |
| Maietta, A | 1 |
| Soulières, D | 1 |
| Blais, N | 1 |
| Cudmore, J | 1 |
| Seftel, M | 1 |
| Sisler, J | 1 |
| Zarychanski, R | 1 |
| Kletzel, M | 1 |
| Powers, K | 1 |
| Hayes, M | 1 |
| Aaldriks, AA | 1 |
| Giltay, EJ | 1 |
| Nortier, JW | 1 |
| van der Geest, LG | 1 |
| Tanis, BC | 1 |
| Ypma, P | 1 |
| le Cessie, S | 1 |
| Maartense, E | 1 |
| Bellakhal, S | 1 |
| Ben Kaab, B | 1 |
| Teyeb, Z | 1 |
| Souissi, A | 1 |
| Derbel, F | 1 |
| Douggui, MH | 1 |
| Lee, GW | 1 |
| Kang, JH | 1 |
| Kim, IS | 1 |
| Kim, HG | 1 |
| Ko, GH | 1 |
| Lee, JH | 1 |
| Kim, DC | 1 |
| Song, DH | 1 |
| Yang, JW | 1 |
| Lee, JS | 1 |
| Kasamon, YL | 1 |
| Brodsky, RA | 1 |
| Borowitz, MJ | 1 |
| Ambinder, RF | 1 |
| Crilley, PA | 1 |
| Cho, SY | 1 |
| Tsai, HL | 1 |
| Smith, BD | 1 |
| Gladstone, DE | 1 |
| Carraway, HE | 1 |
| Huff, CA | 1 |
| Matsui, WH | 1 |
| Bolaños-Meade, J | 1 |
| Jones, RJ | 1 |
| Swinnen, LJ | 1 |
| Jarfaut, A | 1 |
| Santucci, R | 1 |
| Levêque, D | 1 |
| Herbrecht, R | 1 |
| Jones, JA | 1 |
| Avritscher, EB | 1 |
| Cooksley, CD | 1 |
| Michelet, M | 1 |
| Bekele, BN | 1 |
| Elting, LS | 1 |
| Sun, XF | 1 |
| Zhen, ZJ | 1 |
| Lui, DG | 1 |
| Xia, Y | 1 |
| He, YJ | 1 |
| Wang, ZH | 1 |
| Lin, JY | 1 |
| Guan, ZZ | 1 |
| Cummins, DL | 1 |
| Mimouni, D | 1 |
| Tzu, J | 1 |
| Owens, N | 1 |
| Anhalt, GJ | 1 |
| Meyerle, JH | 1 |
| Liu, Y | 1 |
| Ke, XY | 1 |
| Ma, J | 1 |
| Shen, ZX | 1 |
| Zhang, XH | 1 |
| Du, X | 1 |
| Zhao, YM | 1 |
| Lv, JQ | 1 |
| Zhan, ZM | 1 |
| Zeng, XY | 1 |
| Xu, XH | 1 |
| Lu, ZS | 1 |
| Gemmati, D | 1 |
| Ongaro, A | 1 |
| Tognazzo, S | 1 |
| Catozzi, L | 1 |
| Federici, F | 1 |
| Mauro, E | 1 |
| Della Porta, M | 1 |
| Campioni, D | 1 |
| Bardi, A | 1 |
| Gilli, G | 1 |
| Pellati, A | 1 |
| Caruso, A | 1 |
| Scapoli, GL | 1 |
| De Mattei, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intravenous Methotrexate 1g/m2 as Central Nervous System Prophylaxis for High Risk Diffuse Large B Cell Lymphoma: a Prospective, Phase III, Randomized, Controlled Study[NCT05054426] | Phase 3 | 488 participants (Anticipated) | Interventional | 2021-10-08 | Recruiting | ||
| Phase II Study of Oral PRednisone 5 mg Bid Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of Vascular Endothelial Growth Factor Receptor-tyrosine Kinase Inhibitors[NCT02479490] | Phase 2 | 8 participants (Actual) | Interventional | 2015-09-22 | Terminated | ||
| Phase II Study of Intensified CVP, Rituximab, and High Dose Cyclophosphamide for Adult Burkitt or Burkitt-Like Lymphoma[NCT00133991] | Phase 2 | 23 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| A Randomized Study of a New Medical Device for Oral Mucositis (MDOM Trial)[NCT05104268] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2021-11-30 | Not yet recruiting | ||
| A Phase 1/Phase 2 Study for the Prevention of Oral Mucositis (SPOM)[NCT05338398] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2022-04-15 | Enrolling by invitation | ||
| Phase I Study of Multiple Ascending Dose, to Investigate the Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy[NCT05308732] | Phase 1 | 36 participants (Anticipated) | Interventional | 2021-05-11 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of participants experiencing at least one grade 3-5 adverse event (by CTCAE 3.0 criteria). (NCT00133991)
Timeframe: Up to 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| R-CVP + HiCy | 21 |
Percentage of participants alive without relapse at 1 year and 3 years. (NCT00133991)
Timeframe: 1 year and 3 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 1 year | 3 years | |
| R-CVP + HiCy | 52 | 52 |
Number of participants who have a complete or partial remission (2007 International Working Group criteria). (NCT00133991)
Timeframe: Up to 3 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Complete remission | Partial remission | |
| R-CVP + HiCy | 11 | 2 |
Percentage of participants alive at 1 year and at 3 years. (NCT00133991)
Timeframe: 1 year and 3 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 1 year | 3 years | |
| R-CVP + HiCy | 57 | 57 |
Percentage of participants experiencing central nervous system (CNS) and systemic relapse. (NCT00133991)
Timeframe: Up to 6 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Systemic relapse only | Systemic and CNS relapse | |
| R-CVP + HiCy | 3 | 2 |
1 review available for prednisone and Mucositis
| Article | Year |
|---|---|
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
4 trials available for prednisone and Mucositis
| Article | Year |
|---|---|
A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; | 2017 |
Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; C | 2006 |
[Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
Topics: Adolescent; Adult; Aged; Agranulocytosis; Antibiotics, Antineoplastic; Antineoplastic Combined Chemo | 2006 |
10 other studies available for prednisone and Mucositis
| Article | Year |
|---|---|
Intravenous methotrexate at a dose of 1 g/m
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cerebrospinal Fluid; C | 2020 |
Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab.
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2018 |
Methotrexate and trimethoprim-sulfamethoxazole: toxicity from this combination continues to occur.
Topics: Aged; Anti-Infective Agents; Crohn Disease; Diarrhea; Drug Interactions; Female; Humans; Immunosuppr | 2014 |
Scurvy: a new problem for patients with chronic GVHD involving mucous membranes; an easy problem to resolve.
Topics: Administration, Oral; Adolescent; Adult; Ascorbic Acid; Ascorbic Acid Deficiency; Child; Chronic Dis | 2014 |
Prognostic significance of geriatric assessment in combination with laboratory parameters in elderly patients with aggressive non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2015 |
[Systemic lupus erythematosus presenting as Stevens-Johnson syndrome].
Topics: Adult; Anemia; Arthralgia; Autoantibodies; Complement C3; Critical Care; Facial Dermatoses; Female; | 2015 |
Is inactivation of O6-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy?
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2009 |
Severe methotrexate toxicity due to a concomitant administration of ciprofloxacin.
Topics: Adult; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Ant | 2013 |
Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody Formation; Antineopla | 2007 |
Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antimetabolites, Antineoplastic | 2007 |